|
There are uncountable patients worldwide on low-dose aspirin for a variety of conditions, yet few treatments are handy to treat the damage that can be caused to the lining of the stomach and upper intestine. The Eminent trial, reported in an Article Online First and in an upcoming edition of The Lancet, shows that famotidine is productive in the prevention of stomach and upper intestinal ulcers, and damage to the gullet.
Low-portion aspirin (75mg-325mg) is one of the most widely used drugs in the earth. Increasingly, it is being bought over the counter or prescribed for its anti-clotting vim in the heart and brain, and in patients with diabetes. Despite the benefits of aspirin use, its upland has been accompanied by a rise in gastrointestinal complications, such as peptic chancre bleeding, perforation, and sometimes death. Proton-pump inhibitors (PPIs), such as omeprazole and lansoprazole, can foil such ulcers but there have been concerns about payment, safety, and risk of interaction with clopidogrel, another anti-clotting medicate which is often prescribed with aspirin. In this phase III randomised, controlled woe (the FAMOUS study), Dr Ali S Taha, Crosshouse Hospital, Kilmarnock, UK and University of Glasgow, UK, and colleagues planned the effect famotidine, which has a different mechanism of action to proton-deliver inhibitors and belongs to a group of drugs called H2-receptor antagonists. Famotidine lowers acidity by binding to the histamine particles in the stomach, and is broken down by different enzymes in the liver. This explains its gentler action compared with proton-pump inhibitors, particularly in patients requiring the other anti-clotting drug, clopidogrel.
Matured patients from Crosshouse Hospital were eligible for the study if they were attractive aspirin 75mg-325mg per day with or without cardioprotective drugs. Patients were given famotidine 20mg twice daily (204 patients) or placebo twice regular (200 patients). They were then given an endoscopic probe at 12 weeks. The researchers found that stomach ulcers had developed in 3% of patients allowed famotidine compared with 15% given placebo. Upper-intestinal or duodenal ulcers were rest in just one patient (0.5%) in the famotidine group compared with 17% of those disposed placebo. Gullet ulcers occurred in 4% of famotidine patients compared with 19% of placebo patients. There were fewer adverse events in the famotidine union (9 vs 15 placebo). The authors conclude: "Famotidine is paraphernalia in the prevention of gastric and duodenal ulcers, and erosive oesophagitis in patients alluring low-dose aspirin."
They add: "There is ungenerous doubt that aspirin and other anti-clotting drugs are remarkably useful in the prevention of heart, brain, and other vascular diseases, this reason their increasing use world-wide. Patients on such drugs should take up using them as advised by their family doctors or hospital specialists. Notwithstanding how, everybody should be aware that aspirin use can also be associated with a make of gastrointestinal or digestive system problems, which sometimes can be serious. The results of this probing widen the options for the prevention of such problems particularly when more than one clotting hypnotic is required."
In an accompanying Comment, Dr Chris Hawkey, Nottingham Digestive Diseases Focal point, University Hospital, Nottingham, UK, says: "Whilst NSAIDs produce ulcers that then bleed, aspirin may provokes bleeding from ulcers that arose by other means, mostly H.pylori infection. Some, but not all, evidence suggests that H. pylori eradication may be adequate to prevent ulcer bleeding in aspirin users. This simple artifice is an important question that merits answer through an outcome analyse since there is the potential to make aspirin use safer. In the meantime, famotidine seems a cloth alternative to a PPI." |
Categories